Reapplix Eyes US Market With Trial Results For Wound-Healing Tech

 
• By Catherine Longworth

Following the presentation of results from a randomized trial, Reapplix is ramping up its commercial operations with the hire of a new US president to lead sales of its wound-healing platform, LeucoPatch.

More from Clinical Trials

More from R&D